Sino-Argi Leading Biosciences (603970) — Working Capital to Net Assets Ratio
Sino-Argi Leading Biosciences (603970) has a Working Capital to Net Assets ratio of 86.6% as of March 2026. Working capital of CN¥1.54 Billion (current assets of CN¥6.28 Billion minus current liabilities of CN¥4.74 Billion) is measured against net assets of CN¥1.78 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial flexibility index of Sino-Argi Leading Biosciences to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sino-Argi Leading Biosciences Working Capital to Net Assets (2012–2025)
This chart shows how Sino-Argi Leading Biosciences's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 86.6%, reflecting working capital of CN¥1.54 Billion against net assets of CN¥1.78 Billion CNY. See how many days can Sino-Argi Leading Biosciences fund operations to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Sino-Argi Leading Biosciences (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sino-Argi Leading Biosciences from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Sino-Argi Leading Biosciences (603970) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 86.5% | CN¥1.50 Billion | CN¥1.73 Billion | CN¥4.65 Billion | CN¥3.15 Billion | ▲ +0.2 pp |
| 2024 | 86.3% | CN¥1.45 Billion | CN¥1.68 Billion | CN¥5.35 Billion | CN¥3.90 Billion | ▲ +1.6 pp |
| 2023 | 84.7% | CN¥1.35 Billion | CN¥1.59 Billion | CN¥5.74 Billion | CN¥4.39 Billion | ▼ -6.0 pp |
| 2022 | 90.8% | CN¥1.35 Billion | CN¥1.48 Billion | CN¥5.98 Billion | CN¥4.63 Billion | ▲ +6.8 pp |
| 2021 | 83.9% | CN¥1.07 Billion | CN¥1.28 Billion | CN¥4.50 Billion | CN¥3.43 Billion | ▼ -1.1 pp |
| 2020 | 85.1% | CN¥972.54 Million | CN¥1.14 Billion | CN¥3.83 Billion | CN¥2.86 Billion | ▲ +0.9 pp |
| 2019 | 84.1% | CN¥878.76 Million | CN¥1.04 Billion | CN¥2.55 Billion | CN¥1.68 Billion | ▲ +2.1 pp |
| 2018 | 82.0% | CN¥784.71 Million | CN¥957.07 Million | CN¥2.39 Billion | CN¥1.61 Billion | ▲ +2.3 pp |
| 2017 | 79.7% | CN¥690.46 Million | CN¥866.35 Million | CN¥2.58 Billion | CN¥1.89 Billion | ▼ -42.1 pp |
| 2016 | 121.8% | CN¥525.44 Million | CN¥431.42 Million | CN¥2.42 Billion | CN¥1.89 Billion | ▲ +16.0 pp |
| 2015 | 105.8% | CN¥364.44 Million | CN¥344.56 Million | CN¥2.45 Billion | CN¥2.08 Billion | ▼ -54.7 pp |
| 2014 | 160.5% | CN¥466.06 Million | CN¥290.44 Million | CN¥1.92 Billion | CN¥1.45 Billion | ▲ +43.4 pp |
| 2013 | 117.1% | CN¥307.50 Million | CN¥262.68 Million | CN¥1.62 Billion | CN¥1.31 Billion | ▲ +26.6 pp |
| 2012 | 90.4% | CN¥218.54 Million | CN¥241.63 Million | CN¥1.21 Billion | CN¥990.93 Million | — |